Clinical Trial Detail

NCT ID NCT01323517
Title Addition of Ipilimumab (MDX-010) To Isolated Limb Infusion (ILI) With Standard Melphalan and Dactinomycin In The Treatment of Advanced Unresectable Melanoma of The Extremity
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Memorial Sloan Kettering Cancer Center
Indications

melanoma

Therapies

Dactinomycin + Ipilimumab + Melphalan

Age Groups: senior adult

No variant requirements are available.